Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM, Laus AC, Melendez ME, de Carvalho AC, Sorroche BP, De Marchi PR, Evangelista AF, Scapulatempo-Neto C, de Souza Viana L, Carvalho AL. Arantes LM, et al. Among authors: de carvalho ac, de souza viana l, de marchi pr. Oncotarget. 2017 Feb 7;8(6):9911-9921. doi: 10.18632/oncotarget.14253. Oncotarget. 2017. PMID: 28039483 Free PMC article.
The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer.
De Marchi P, Melendez ME, Laus AC, Kuhlmann PA, de Carvalho AC, Arantes LMRB, Evangelista AF, Andrade ES, de Castro G Junior, Reis RM, Carvalho AL, de Souza Viana L. De Marchi P, et al. Among authors: de souza viana l. Oral Oncol. 2019 Nov;98:48-52. doi: 10.1016/j.oraloncology.2019.09.013. Epub 2019 Sep 17. Oral Oncol. 2019. PMID: 31539757
Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma.
Oliveira-Silva RJ, Carolina de Carvalho A, de Souza Viana L, Carvalho AL, Reis RM. Oliveira-Silva RJ, et al. Among authors: de souza viana l. Recent Pat Anticancer Drug Discov. 2016;11(2):170-83. doi: 10.2174/1574892811666160309121238. Recent Pat Anticancer Drug Discov. 2016. PMID: 26955963
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Silva-Oliveira RJ, Silva VA, Martinho O, Cruvinel-Carloni A, Melendez ME, Rosa MN, de Paula FE, de Souza Viana L, Carvalho AL, Reis RM. Silva-Oliveira RJ, et al. Among authors: de paula fe, de souza viana l. Cell Oncol (Dordr). 2016 Jun;39(3):253-63. doi: 10.1007/s13402-016-0270-z. Epub 2016 Feb 26. Cell Oncol (Dordr). 2016. PMID: 26920031
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
de Souza Viana L, de Aguiar Silva FC, Andrade Dos Anjos Jacome A, Calheiros Campelo Maia D, Duarte de Mattos M, Arthur Jacinto A, Elias Mamere A, Boldrini Junior D, de Castro Capuzzo R, Roberto Santos C, Lopes Carvalho A. de Souza Viana L, et al. Among authors: de aguiar silva fc, de castro capuzzo r. Head Neck. 2016 Apr;38 Suppl 1:E970-80. doi: 10.1002/hed.24137. Epub 2015 Jul 18. Head Neck. 2016. PMID: 26031625 Clinical Trial.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Machiels JP, et al. Among authors: de castro g jr, de souza viana l. Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16. Lancet Oncol. 2015. PMID: 25892145 Clinical Trial.
24 results